For information on our ongoing IRX-2 (citoplurikin) clinical trials
click here.
|
IRX Therapeutics is a privately held immunotherapy company
focusing on the discovery and commercial-
ization of
treatments for advanced cancer and viral diseases. Founded
in 1994 by John W. Hadden, MD, a pioneer in the field of
Immunopharmacology, IRX Therapeutics is developing an
innovative approach that stimulates a coordinated TH1-specific cellular
immune response to treat human diseases. This immune
response is essential for the eradication of most viruses and
tumors, and relies on the effective functioning of dendritic
cells, macrophages, and T-cells.
Currently, there is a lack of drugs that stimulate the cellular
immune response. IRX Therapeutics has two development
programs designed to fill this void: Cancer and Viral disease
treatments.
The overall goal of these treatments is to increase survival
rates and improve quality of life for patients who suffer from
these diseases.
|
|
